Testing BMS-986488 for advanced malignant tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety, tolerability, and anti-cancer activity of BMS-986488, both as a standalone treatment and in combination with other therapies, in patients with advanced malignant tumors. Participants will include those with various types of cancers, including colorectal cancer, renal cell carcinoma, and non-small cell lung cancer. The study aims to determine the effectiveness of this experimental treatment in managing these serious conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant must be ≥ 18 years of age.
* Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
* Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).
* Parts 2A, 1D, 2D: ccRCC.

  i) Part 1B: solid tumors with KRAS G12C mutation.

ii) Part 2B: NSCLC with KRAS G12C mutation.

iii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.

* Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
* Participants must have measurable disease per RECIST v1.1.

Exclusion Criteria:

* Untreated central nervous system (CNS) metastases.
* Leptomeningeal metastasis (carcinomatous meningitis).
* Impaired cardiac function or clinically significant cardiac disease.
* For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.

  i) History of pneumonitis or interstitial lung disease (ILD).

ii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

\- Other protocol-defined inclusion/exclusion criteria apply.

Where it's running

• John Theurer Cancer Center at Hackensack University Medical Center
  Hackensack, New Jersey, United States Recruiting
• The West Clinic, PLLC dba West Cancer Center
  Germantown, Tennessee, United States Recruiting
• BC Cancer Vancouver
  Vancouver, British Columbia, Canada Recruiting
• Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus
  Québec, Quebec, Canada Recruiting
• Local Institution - 0020
  Allentown, Pennsylvania, United States Active not recruiting
• Local Institution - 0025
  Dallas, Texas, United States Withdrawn

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if TQB3142 is tolerated and how it behaves in people with advanced cancers

  This early-phase test checks whether TQB3142 injections are safe to use and how the drug moves through the body in adults with advanced tumors.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Guangzhou, Guangdong and 4 other locations · NCT07338838

• TQB6411 injection for advanced EGFR/c‑Met–expressing solid tumors

  This phase 1 trial tests TQB6411, an antibody–drug that targets EGFR and c‑Met, to try to kill tumor cells in adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 18 other locations · NCT07043751

• SPGL008 given by IV or under-the-skin injection for advanced malignant tumors

  This trial will test whether SPGL008 given intravenously or under the skin is safe and shows early signs of benefit in adults with advanced malignant tumors.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Chongqing, Chongqing Municipality · NCT07038005

• Phase 1 SSGJ-612 for advanced HER2‑positive solid tumors

  This trial will test SSGJ-612, a new drug, in adults with advanced HER2‑expressing solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Luoyang, Henan · NCT07032298

• SSGJ-709 for people with advanced malignant tumors

  This clinical trial will try SSGJ-709, an experimental intravenous drug given every three weeks, in people with advanced malignant tumors who have exhausted or cannot receive standard treatments to see if it is safe and shows anti-tumor activity.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Adelaide · NCT07016490

• Investigating JMT108 Injection for Advanced Malignant Tumors

  This study is testing a new injection called JMT108 to see if it is safe and can help people with advanced tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Shanghai JMT-Bio Inc. · Shanghai, Shanghai Municipality · NCT06877650

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.